Among them, 3,3′-deoxy-3,3′-bis-(4-[m-fluorophenyl]-1H-1,2,3-triazol-1-yl)-thio-digalactoside (TD139; Fig. 1) is the most potent inhibitor of galectins-1 and -39, 20, and has been approved by the United States Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis. Here, LGALS1 is linked to pulmonary fibrosis.